Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study

被引：0
|
作者：
Rapaport, M
Wilcox, C
Heiser, J
Londborg, P
Schwartz, G
机构：
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[2] Pharmacol Res Inst, Los Alamitos, CA USA
[3] Summit Res Network, Seattle, WA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [21] Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study
    Horikoshi, S. H.
    Miura, I. M.
    Yamamoto, S. Y.
    Abe, O. A.
    Ito, M. I.
    Watanabe, K. W.
    Nozaki, K. N.
    Kaneko, H. K.
    Yabe, H. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S861 - S861
  • [22] Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder
    Wozniak, Janet
    Mick, Eric
    Waxmonsky, James
    Kotarski, Meghan
    Hantsoo, Liisa
    Biederman, Joseph
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (05) : 539 - 545
  • [23] Duloxetine in the treatment of major depressive disorder: an open-label study
    James I Hudson
    David G Perahia
    Inmaculada Gilaberte
    Fujun Wang
    John G Watkin
    Michael J Detke
    BMC Psychiatry, 7
  • [24] Duloxetine in the treatment of major depressive disorder: an open-label study
    Hudson, James I.
    Perahia, David G.
    Gilaberte, Inmaculada
    Wang, Fujun
    Watkin, John G.
    Detke, Michael J.
    BMC PSYCHIATRY, 2007, 7 (1) : 43
  • [25] Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study
    Ahearn, EP
    Mussey, M
    Johnson, C
    Krohn, A
    Krahn, D
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (01) : 29 - 33
  • [26] MAJOR DEPRESSIVE DISORDER, ANHEDONIA, AND AGOMELATINE: AN OPEN-LABEL STUDY
    Martinotti, G.
    Di Iorio, G.
    Guglielmo, R.
    De Berardis, D.
    Janiri, L.
    Di Giannantonio, M.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [27] MAJOR DEPRESSIVE DISORDER, ANHEDONIA AND AGOMELATINE: AN OPEN-LABEL STUDY
    di Giannantonio, M.
    Di Iorio, G.
    Guglielmo, R.
    De Berardis, D.
    Conti, C. M.
    Acciavatti, T.
    Cornelio, M.
    Martinotti, G.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2011, 25 (01): : 109 - 114
  • [28] Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine
    Fava, M
    McGrath, PJ
    Sheu, WP
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) : 365 - 369
  • [29] Efficacy and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Shin, D.
    Hong, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S300 - S300
  • [30] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Lee, Hwang-Bin
    Yoon, Bo-Hyun
    Kwon, Young-Joon
    Woo, Young Sup
    Lee, Jung-Goo
    Kim, Moon-Doo
    Bahk, Won-Myong
    CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 743 - 753
12345